Results 91 to 100 of about 6,419,132 (171)

Adjuvant therapy in glucagon-like peptide-1 receptor agonist treatment: Enhancement of efficacy and mitigation of adverse events. A review

open access: yesConsilium Medicum
Glucagon-like peptide-1 receptor agonists (arGLP-1) demonstrate considerable efficacy in the management of obesity and type 2 diabetes mellitus. Nonetheless, their clinical application is often restricted due to gastrointestinal adverse events, such as ...
Dmitry N. Andreev, Yury A. Kucheryavyy
doaj   +1 more source

Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease

open access: yes, 2008
Background and aims: increased epithelial cell proliferation may be detected in diverticular disease, but antibiotics have failed in reducing it. We assess therefore the effect of mesalazine on epithelial cell proliferation in diverticular disease ...
ELISEI W   +11 more
core   +1 more source

Diarrhea management: from pathophysiology to microbiota modulation

open access: yesTherapeutic Advances in Gastroenterology
Diarrhea, whether acute or chronic, is a common clinical condition with numerous causes that collectively impose significant health, economic, social, and psychological burdens worldwide.
Giovanni Marasco   +6 more
doaj   +1 more source

Efficacy of Lactobacillus paracasei sub. paracasei F19 on abdominal symptoms in patients with symptomatic uncomplicated diverticular disease: A pilot study

open access: yes, 2011
Aim. The standard therapeutic approach for symptomatic uncomplicated diverticular disease (DD) remains to be defined, and only a few studies have tested the efficacy of probiotics in these patients. Methods.
ANNIBALE, Bruno   +7 more
core  

Probiotics and Diverticular Disease. Evidence-based?

open access: yes, 2016
Diverticular disease (DD) is a common gastrointestinal condition. Clinical spectrum ranges from asymptomatic diverticulosis to symptomatic uncomplicated or complicated DD. Symptoms related to uncomplicated DD are not specific and may be indistinguishable
ANNIBALE, Bruno, LAHNER, EDITH
core   +1 more source

Gut Microbiota May Predict the Short-Term Recurrence of Symptomatic Uncomplicated Diverticular Disease

open access: yesJournal of Gastrointestinal and Liver Diseases
Background and Aims: Symptomatic Uncomplicated Diverticular Disease (SUDD) may recur, but it is still unknown whether the gut microbiota (GM) may play a role. We aimed to analyze whether GM plays a role in short-term (6 months) relapse in SUDD patients for whom GM data were retrospectively available.
Antonio, Tursi   +20 more
openaire   +2 more sources

Management of symptomatic uncomplicated diverticular disease (SUDD) of the colon with Clostridium butyricum CBM588 versus rifaximin: a retrospective cross-sectional study. [PDF]

open access: yesInt J Colorectal Dis
Urgesi R   +13 more
europepmc   +1 more source

Efficacy of long term cyclic administration of the poorly absorbed Rifaximin in symptomatic, uncomplicted colonic diverticular disease

open access: yes, 2007
Aim: To comparatively ate the long term efficacy of Rifaximin and dietary fibers in reducing symptoms and/or complication frequency in symptomatic, uncomplicated diverticular disease. Methods: 307 patients (118 males, 189 females, age range: 40-80 years)
Roda, Enrico   +7 more
core  

[Modern indications on the medical treatment of symptomatic diverticular disease].

open access: yes, 2006
Authors refer about their experience on treatment of symptomatic diverticular disease both with antibiotic and anti-inflammatory drugs. They confirm the observation of other Authors on effectiveness of this new therapeutic approach versus traditional ...
DI FULVIO, Annunziata   +5 more
core  

Site and duration of abdominal pain discriminate symptomatic uncomplicated diverticular disease from previous diverticulitis patients. [PDF]

open access: yesIntern Emerg Med
Carabotti M   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy